Clinical Trials in New York

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Status

Study

Lead sponsor

Phase

Enrol

US states

Start

Recruiting

Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

NCT07185997Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer, EGFR P-Loop and Alpha C-Helix Compressing

ArriVent BioPharma, Inc.

Phase 3

480

California, Colorado, Illinois, Michigan, New York, Ohio, Pennsylvania, Texas

2025-12-17

Active, closed

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Participants

NCT06269133Advanced Non-small Cell Lung Cancer

Regeneron Pharmaceuticals

Observational

1,000

New York

2024-02-21

Active, closed

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

NCT05557591Advanced Non-Small Cell Lung Cancer

Regeneron Pharmaceuticals

Phase 2

California, Kentucky, New Mexico, New York, North Carolina, Texas, Virginia, Washington

2023-04-21

Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

NCT05099172Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation

Bayer

Phase 1/2

400

Arizona, California, Georgia, Maryland, Massachusetts, Michigan, New York, Tennessee

2021-10-25

Active, closed

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

NCT02143466Advanced Non Small Cell Lung Cancer

AstraZeneca

Phase 1

344

Georgia, Massachusetts, New York, Pennsylvania, Tennessee

2014-08-05

Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-usa/state/new-york

Query this register directly

GET /api/trials?country=usa&status=recruiting&format=json Try it now →